HomeCompareAZYO vs JEPI

AZYO vs JEPI: Dividend Comparison 2026

AZYO yields 134.23% · JEPI yields 8.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AZYO wins by $14.39M in total portfolio value
10 years
AZYO
AZYO
● Live price
134.23%
Share price
$1.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14.42M
Annual income
$5,849,084.49
Full AZYO calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.40%
Share price
$56.68
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$1,528.62
Full JEPI calculator →

Portfolio growth — AZYO vs JEPI

📍 AZYO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAZYOJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AZYO + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AZYO pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AZYO
Annual income on $10K today (after 15% tax)
$11,409.40/yr
After 10yr DRIP, annual income (after tax)
$4,971,721.82/yr
JEPI
Annual income on $10K today (after 15% tax)
$714.16/yr
After 10yr DRIP, annual income (after tax)
$1,299.33/yr
At 15% tax rate, AZYO beats the other by $4,970,422.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AZYO + JEPI for your $10,000?

AZYO: 50%JEPI: 50%
100% JEPI50/50100% AZYO
Portfolio after 10yr
$7.23M
Annual income
$2,925,306.56/yr
Blended yield
40.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AZYO right now

AZYO
Analyst Ratings
4
Buy
Consensus: Buy
Price Target
$10.25
+587.9% upside vs current
Range: $10.00 — $10.50
Altman Z
-3.7
Piotroski
6/9
JEPI
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AZYO buys
0
JEPI buys
0
No recent congressional trades found for AZYO or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAZYOJEPI
Forward yield134.23%8.40%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$14.42M$29.0K
Annual income after 10y$5,849,084.49$1,528.62
Total dividends collected$13.23M$11.7K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: AZYO vs JEPI ($10,000, DRIP)

YearAZYO PortfolioAZYO Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$24,123$13,422.82$11,260$840.19+$12.9KAZYO
2$56,073$30,261.33$12,641$907.94+$43.4KAZYO
3$125,738$65,739.74$14,150$978.20+$111.6KAZYO
4$272,310$137,770.90$15,795$1,050.85+$256.5KAZYO
5$570,223$278,851.11$17,584$1,125.74+$552.6KAZYO
6$1,155,858$545,719.55$19,526$1,202.74+$1.14MAZYO
7$2,270,590$1,033,821.54$21,628$1,281.69+$2.25MAZYO
8$4,327,530$1,897,998.85$23,898$1,362.43+$4.30MAZYO
9$8,011,211$3,380,754.03$26,347$1,444.79+$7.98MAZYO
10$14,421,080$5,849,084.49$28,982$1,528.62+$14.39MAZYO

AZYO vs JEPI: Complete Analysis 2026

AZYOStock

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Full AZYO Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this AZYO vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AZYO vs SCHDAZYO vs OAZYO vs KOAZYO vs MAINAZYO vs JEPQAZYO vs XYLDAZYO vs DIVOAZYO vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.